2014 Alzheimer’s Drug Discovery Foundation’s Research Funding Priorities
The Alzheimer’s Drug Discovery Foundation (ADDF) funds four different categories of research; drug discovery and preclinical development, early detection, clinical trials and prevention. The ADDF does not fund basic research.
The ADDF is interested in novel targets and therapeutic approaches for Alzheimer’s disease, related dementias and cognitive aging. These areas include, but are not limited to: Energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury, the blood-brain barrier interface, and translatable biomarkers. The ADDF has limited interest in funding anti-amyloid approaches and has limited interest in funding cholinesterase inhibitor programs. For full details on ADDF funding mechanisms and priorities, or to submit an application, visit our website.
2014 Open RFPs
PRECLINICAL DRUG DISOCVERY RFP:
The ADDF accepts Letters of Intent (LOIs) for the “General Request for Proposals” research award programs throughout the year. 2014 deadlines for full proposals are March 5, June 5, September 5, and December 5. LOIs are due at least two weeks prior to the proposal deadlines.
The ADDF has created the Program to Accelerate Clinical Trials (PACT) to increase the number of innovative drugs tested in humans at the crucial proof of concept stage for Alzheimer’s disease. This program will fund biomarker-based, proof-of-concept pilot clinical trials for Alzheimer’s. 2014 deadlines for full proposals are March 5, June 5, September 5 and December 5. LOIs are due at least two weeks prior to the proposal deadlines.
The ADDF will consider financial assistance for relevant NIH grant applications that were scored but not funded in response to certain NIH funding opportunities. Application deadline is rolling.
2014 Full Proposal Deadlines*
*Letter of intent is due two weeks prior to deadline
About the Alzheimer’s Drug Discovery Foundation
The mission of the Alzheimer’s Drug Discovery Foundation (ADDF) is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease, related dementias and cognitive aging. The ADDF has granted nearly $60 million to fund 400 Alzheimer’s drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries. For more information, please visit www.AlzDiscovery.org.
The Alzheimer’s Drug Discovery Foundation (ADDF) launched the ADDF ACCESS program to give the academic and small biotechnology community online access to a marketplace of contract research organizations (CROs), and a network of expert consultants and collaborators who focus on drug discovery for diseases of the central nervous system (CNS). ADDF ACCESS additionally provides educational resources and guidance on the process of selecting and managing a CRO contract. For more information, visit the ADDF ACCESS website and read the editorial in Nature Reviews Drug Discovery.